Staffing, accepted indications, and dose of Phase II cardiac rehabilitation: country income class and time-based comparisons from the International Council of Cardiovascular Prevention and Rehabilitation’s (ICCPR) 2025 Audit Update
- 28 May 2026
- journal article
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Abstract
Aims: To characterize global variation in cardiac rehabilitation (CR) staffing, indications, and prescribed dose by country income classification and compare findings with the International Council of Cardiovascular Prevention and Rehabilitation’s 2016 Global Audit. Methods and results: Cross-sectional REDCap survey of Phase II/post-discharge CR programmes (May–September 2025). Outcomes were multidisciplinary team size/composition, accepted cardiac and non-cardiac indications, and centre-based CR dose. Comparisons were made across World Bank country income classifications and Audit decade (2016 vs. 2025). Of 7025 programmes identified globally, 1505 (median programme response rate = 62%/country) initiated a survey, from 90/113 (80%) countries with CR. CR was delivered by a multidisciplinary team of 7 (median; P25–P75 = 5–8; nurses, physiotherapists, cardiologists, and dietitians most common); teams were smaller in low-income countries (median = 4; P < 0.001), and physician specialty varied. Non-low-income programmes consistently accepted (≥90%) patients with acute coronary syndrome, with programmes in low-income countries less often accepting related interventions (e.g. surgery: low-income 0% vs. high-income 97%; P < 0.01), but non-cardiac indications were more frequently accepted (e.g. primary prevention, diabetes, and lung disease). Acceptance of heart failure increased compared with the previous Audit (70% vs. 87%; P < 0.001). Centre-based programmes prescribed a median of 20 h (P25–P75 = 12–30), typically two sessions/week over 8 weeks. Globally, 65 (72%) countries prescribed a median ≥12 sessions/programme. Programmes in upper-middle-income countries prescribed more sessions (median = 24, P25–P75 = 12–36; P < 0.001). Dose did not differ meaningfully between Audits (P = 0.07). Conclusion: CR programmes globally are offered by small, but multidisciplinary teams. They accept guideline-indicated patients, with applicable variation by context. Insufficient dose in one-quarter of countries underscores investment need.Keywords
Funding Information
- Qatar University International Research Collaboration Co-Fund
- York University (IRCC-2025-648)
- Faculty Mobility for Partnership Building Program of Global Affairs Canada
- Ministerstvo Zdravotnictví Ceské Republiky (65269705)
This publication has 33 references indexed in Scilit:
- Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023JACC, 2025
- Evidence for exercise-based interventions across 45 different long-term conditions: an overview of systematic reviewseClinicalMedicine, 2024
- TITAN TrialJACC: Advances, 2023
- The impact of ICCPR's Global Audit of Cardiac Rehabilitation: where are we now and where do we need to go?eClinicalMedicine, 2023
- Research Quality and Impact of Cardiac Rehabilitation in Cancer SurvivorsJACC: Cardiooncology, 2022
- Nature of Cardiac Rehabilitation Around the GlobeeClinicalMedicine, 2019
- Cardiac Rehabilitation Availability and Density around the GlobeeClinicalMedicine, 2019
- Funding sources and costs to deliver cardiac rehabilitation around the globe: Drivers and barriersInternational Journal of Cardiology, 2019
- Effect of Cardiac Rehabilitation Dose on Mortality and Morbidity: A Systematic Review and Meta-regression AnalysisMayo Clinic Proceedings, 2017
- Cardiac Rehabilitation Delivery Model for Low-Resource Settings: An International Council of Cardiovascular Prevention and Rehabilitation Consensus StatementProgress in Cardiovascular Diseases, 2016